Equities

Sareum Holdings PLC

Sareum Holdings PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)170.00
  • Today's Change-5.00 / -2.86%
  • Shares traded80.95k
  • 1 Year change-46.88%
  • Beta-0.2102
Data delayed at least 20 minutes, as of Sep 28 2022 16:31 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sareum Holdings plc is a United Kingdom-based specialist drug development company. The Company is engaged in the discovery and development of new therapeutic drugs by a combination of skills in biology, computational chemistry and medicinal chemistry. The Company is focused advancing the dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the cytokine storm immune system overreaction to Covid-19 and other viral infections (SDC-1801) and cancer immunotherapy (SDC-1802). The Company has interest in SRA737, which is a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and deoxyribonucleic (DNA) damage repair mechanisms. In addition, the Company manufactures SDC-1801 drug substance and oral capsule formulation under good manufacturing practice (GMP) conditions is on track to enable the Phase Ia trial.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-1.81m
  • Incorporated2004
  • Employees6.00
  • Location
    Sareum Holdings PLCUnit 2ALangford Arch, London Road, PampisfordCAMBRIDGE CB22 3FXUnited KingdomGBR
  • Phone+44 122 349 7700
  • Fax+44 122 349 7701
  • Websitehttp://www.sareum.co.uk/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Open Orphan PLC32.93m-1.06m61.05m218.00--2.9420.791.85-0.0016-0.00160.04910.0310.7473--2.95151,045.90-2.41-21.58-4.85-39.82-----3.23-25.221.162.530.0981--78.9320.2399.31--62.75--
4Basebio PLC-100.00bn-100.00bn70.83m---------------------------------------------------26.84---349.93------
Eco Animal Health Group Plc82.20m-686.00k76.19m221.00--0.928459.150.9269-0.0101-0.01011.211.210.71321.862.74371,923.10-0.61177.78-0.84510.0642.7546.98-0.857710.422.4269.120.019853.51-22.176.00-109.35---18.83--
Arecor Therapeutics PLC1.39m-7.43m80.79m37.00--5.06--58.08-0.3249-0.32490.06040.52370.0681--0.684137,594.05-36.37---41.23-------534.19--6.24-535.050.0115---31.79---124.13------
e-Therapeutics plc477.00k-8.07m95.20m32.00--3.40--199.59-0.0169-0.01690.0010.05440.0217--3.3114,906.25-36.62-37.71-38.29-40.40100.00100.00-1,691.82-1,812.91----0.0239--50.47---119.06--42.31--
Faron Pharmaceuticals Oy0.00-21.37m104.37m37.00---------0.4063-0.40630.00-0.08450.00----0.00-166.26-165.50-342.16-391.61-------487,178.90----1.73-------25.16--38.80--
Scancell Holdings Plc0.00-8.41m104.96m25.00--4.63-----0.0105-0.01050.000.02780.00----0.00-21.98-48.49-24.78-52.14------------0.2598-------181.09------
Futura Medical plc.0.00-5.87m106.72m11.00--14.45-----0.0204-0.02040.000.02570.00----0.00-52.23-65.78-57.68-86.83-------6,607.25----0.00-------105.85--123.78--
Creo Medical Group PLC25.90m-28.13m108.92m316.00--1.78--4.21-0.1601-0.16010.14710.3370.30811.844.0989,303.45-33.47---42.12--46.38---108.63--2.19-215.970.1648--166.85---21.06------
Sareum Holdings Plc0.00-1.81m117.42m6.00--20.68-----0.0273-0.02730.000.08340.00----0.00-48.39-49.67-51.44-54.40-------10,610.04----0.00---100.00---52.18------
Allergy Therapeutics plc79.00m-5.38m119.16m601.00--2.17--1.51-0.0091-0.00910.1190.08540.82732.237.33131,439.30-5.641.01-6.811.3370.7574.38-6.810.92133.16-13.580.1530.007.8311.69-59.11--15.77--
Niox Group PLC28.80m13.20m153.15m128.0012.442.098.755.320.02940.03050.06350.17450.3173.003.97225,000.0014.53-11.6916.73-13.9969.7976.1945.83-81.992.00--0.0201--16.743.85108.58---22.16--
Animalcare Group Plc74.02m-77.00k166.76m211.00--2.1220.032.25-0.0013-0.00131.231.310.63152.998.57350,824.70-0.0657---0.0768--53.25---0.104--0.96647.160.1221--5.01---132.91------
Bioventix PLC10.50m6.62m174.51m17.0026.6117.9425.8116.631.261.262.001.870.96152.512.78617,437.1060.6552.3765.6955.5592.8392.3063.0865.2910.60123.630.0070.905.9814.65-6.5414.0165.4327.46
Data as of Sep 28 2022. Currency figures normalised to Sareum Holdings PLC's reporting currency: UK Pound GBX

Institutional shareholders

24.42%Per cent of shares held by top holders
HolderShares% Held
Hargreaves Lansdown Stockbrokers Ltd.as of 02 Jul 20227.53m11.06%
Hargreaves Lansdown Asset Management Ltd.as of 02 Jul 20224.17m6.13%
HSBC Global Asset Management (UK) Ltd.as of 02 Jul 20222.91m4.27%
Jarvis Investment Management Ltd.as of 02 Jul 2022790.00k1.16%
IG Markets Ltd.as of 02 Jul 2022487.00k0.72%
HSBC Bank Plc (Market-Maker)as of 02 Jul 2022232.00k0.34%
Rowan Dartington & Co. Ltd. (Broker)as of 02 Jul 2022170.00k0.25%
Tilney Investment Management Services Ltd.as of 02 Jul 2022153.00k0.23%
J. M. Finn & Co. Ltd.as of 02 Jul 202292.00k0.14%
KW Investment Management Ltd.as of 02 Jul 202290.00k0.13%
More ▼
Data from 30 Sep 2020 - 02 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.